open access

Vol 56, No 1 (2022)
Invited Review Article
Submitted: 2021-11-29
Accepted: 2022-01-31
Published online: 2022-02-08
Get Citation

Cannabis and cannabinoids: pharmacology and therapeutic potential

Małgorzata Śmiarowska1, Monika Białecka1, Anna Machoy-Mokrzyńska2
·
Pubmed: 35133644
·
Neurol Neurochir Pol 2022;56(1):4-13.
Affiliations
  1. Department of Pharmacokinetics and Therapeutic Drug Monitoring, Pomeranian Medical University, Szczecin, Poland
  2. Department of Experimental and Clinical Pharmacology, Pomeranian Medical University, Szczecin, Poland

open access

Vol 56, No 1 (2022)
INVITED REVIEW ARTICLES — LEADING TOPIC
Submitted: 2021-11-29
Accepted: 2022-01-31
Published online: 2022-02-08

Abstract

Introduction. Cannabis (also known as marijuana) is the most frequently used psychoactive substance in the world. The role of cannabis in medicine is rapidly evolving, and advances in the understanding of its pharmacology have led to numerous proposed uses of these drugs. State of the art. Cannabis contains Δ9-tetrahydrocannabinol and cannabidiol as the primary constituents responsible for pharmacological activity. It is now known that there are at least two types of cannabinoid receptors. CB1 receptors are found mainly in the CNS, and their primary role is to inhibit the release of neurotransmitters. CB2 receptors’ leading role is to modulate cytokine release and immune cell migration. Colocalisation of cannabinoid receptors with other types of nervous system receptors allows them to interact with many other transmitters such as dopamine, noradrenaline, acetylcholine, gamma-aminobutyric acid, serotonin, and glutamic and aspartic acids. Clinical implications. The rapidly expanding understanding regarding cannabinoids led to initial attempts to treat selected diseases with cannabinoid receptor agonists and antagonists. The most promising of these was the potential possibility of treating diseases for which current therapy is unsatisfactory, such as neurological diseases including multiple sclerosis, spastic muscular tension, extrapyramidal system diseases, neurodegenerative diseases and cerebral ischaemia. Attempts to treat psychiatric diseases (e.g. psychoses, neuroses, mood disorders, and alcohol dependence syndrome) with cannabinoids are much less advanced. Future directions. Cannabis and cannabinoids can be widely used to treat several diseases or alleviate symptoms, but their efficacy for specific indications is not always apparent. Further exploration is needed to understand whether the enhanced sensitivity to the cognitive effects of Δ9-THC depends on brain cannabinoid receptor dysfunction, and how these changes contribute to the cognitive deterioration and core pathophysiology symptoms associated with schizophrenia or other neurological and somatoform disorders.

Abstract

Introduction. Cannabis (also known as marijuana) is the most frequently used psychoactive substance in the world. The role of cannabis in medicine is rapidly evolving, and advances in the understanding of its pharmacology have led to numerous proposed uses of these drugs. State of the art. Cannabis contains Δ9-tetrahydrocannabinol and cannabidiol as the primary constituents responsible for pharmacological activity. It is now known that there are at least two types of cannabinoid receptors. CB1 receptors are found mainly in the CNS, and their primary role is to inhibit the release of neurotransmitters. CB2 receptors’ leading role is to modulate cytokine release and immune cell migration. Colocalisation of cannabinoid receptors with other types of nervous system receptors allows them to interact with many other transmitters such as dopamine, noradrenaline, acetylcholine, gamma-aminobutyric acid, serotonin, and glutamic and aspartic acids. Clinical implications. The rapidly expanding understanding regarding cannabinoids led to initial attempts to treat selected diseases with cannabinoid receptor agonists and antagonists. The most promising of these was the potential possibility of treating diseases for which current therapy is unsatisfactory, such as neurological diseases including multiple sclerosis, spastic muscular tension, extrapyramidal system diseases, neurodegenerative diseases and cerebral ischaemia. Attempts to treat psychiatric diseases (e.g. psychoses, neuroses, mood disorders, and alcohol dependence syndrome) with cannabinoids are much less advanced. Future directions. Cannabis and cannabinoids can be widely used to treat several diseases or alleviate symptoms, but their efficacy for specific indications is not always apparent. Further exploration is needed to understand whether the enhanced sensitivity to the cognitive effects of Δ9-THC depends on brain cannabinoid receptor dysfunction, and how these changes contribute to the cognitive deterioration and core pathophysiology symptoms associated with schizophrenia or other neurological and somatoform disorders.

Get Citation

Keywords

cannabis, cannabinoids, THC, cannabinoid receptors

About this article
Title

Cannabis and cannabinoids: pharmacology and therapeutic potential

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 56, No 1 (2022)

Article type

Invited Review Article

Pages

4-13

Published online

2022-02-08

Page views

7673

Article views/downloads

2562

DOI

10.5603/PJNNS.a2022.0015

Pubmed

35133644

Bibliographic record

Neurol Neurochir Pol 2022;56(1):4-13.

Keywords

cannabis
cannabinoids
THC
cannabinoid receptors

Authors

Małgorzata Śmiarowska
Monika Białecka
Anna Machoy-Mokrzyńska

References (33)
  1. Häuser W, Finn DP, Kalso E, et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. Eur J Pain. 2018; 22(9): 1547–1564.
  2. Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006; 58(3): 389–462.
  3. Lafaye G, Karila L, Blecha L, et al. Cannabis, cannabinoids, and health. Dialogues Clin Neurosci. 2017; 19(3): 309–316.
  4. Pertwee RG, Howlett AC, Abood ME, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev. 2010; 62(4): 588–631.
  5. Mackie K. Signaling via CNS cannabinoid receptors. Mol Cell Endocrinol. 2008; 286(1-2 Suppl 1): S60–S65.
  6. Health Canada. Information for health care professionals: Cannabis (marihuana, marijuana) and the cannabinoids. 2018. https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/information-medical-practitioners/information-health-care-professionals-cannabis-cannabinoids (ISBN: 978-0-660-27828-5, last accessed 22/11/2021).
  7. Hillard CJ. The Endocannabinoid Signaling System in the CNS: A Primer. Int Rev Neurobiol. 2015; 125: 1–47.
  8. Compagnucci C, Di Siena S, Bustamante MB, et al. Type-1 (CB1) cannabinoid receptor promotes neuronal differentiation and maturation of neural stem cells. PLoS One. 2013; 8(1): e54271.
  9. Lu HC, Mackie K. An Introduction to the Endogenous Cannabinoid System. Biol Psychiatry. 2016; 79(7): 516–525.
  10. Graczyk M, Łukowicz M, Dzierzanowski T. Prospects for the Use of Cannabinoids in Psychiatric Disorders. Front Psychiatry. 2021; 12: 620073.
  11. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015; 313(24): 2456–2473.
  12. Hejazi N, Zhou C, Oz M, et al. Delta9-tetrahydrocannabinol and endogenous cannabinoid anandamide directly potentiate the function of glycine receptors. Mol Pharmacol. 2006; 69(3): 991–997.
  13. Izzo AA, Borrelli F, Capasso R, et al. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci. 2009; 30(10): 515–527.
  14. Di Marzo V, Stella N, Zimmer A. Endocannabinoid signalling and the deteriorating brain. Nat Rev Neurosci. 2015; 16(1): 30–42.
  15. Trezza V, Campolongo P. The endocannabinoid system as a possible target to treat both the cognitive and emotional features of post-traumatic stress disorder (PTSD). Front Behav Neurosci. 2013; 7: 100.
  16. Silvestri C, Di Marzo V. The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab. 2013; 17(4): 475–490.
  17. Curtis A, Clarke CE, Rickards HE. Cannabinoids for Tourette's Syndrome. Cochrane Database Syst Rev. 2009(4): CD006565.
  18. Corcoran CM, Kimhy D, Stanford A, et al. Temporal association of cannabis use with symptoms in individuals at clinical high risk for psychosis. Schizophr Res. 2008; 106(2-3): 286–293.
  19. Johnson JR, Burnell-Nugent M, Lossignol D, et al. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010; 39(2): 167–179.
  20. Pertwee RG. Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem. 2010; 17(14): 1360–1381.
  21. Fantegrossi WE, Wilson CD, Berquist MD. Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin, and glutamate systems. Drug Metab Rev. 2018; 50(1): 65–73.
  22. Katona I, Freund TF. Multiple functions of endocannabinoid signaling in the brain. Annu Rev Neurosci. 2012; 35: 529–558.
  23. Lutz B, Marsicano G, Maldonado R, et al. The endocannabinoid system in guarding against fear, anxiety and stress. Nat Rev Neurosci. 2015; 16(12): 705–718.
  24. Basavarajappa BS. Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity. Curr Neuropharmacol. 2007; 5(2): 81–97.
  25. Levine A, Clemenza K, Rynn M, et al. Evidence for the Risks and Consequences of Adolescent Cannabis Exposure. J Am Acad Child Adolesc Psychiatry. 2017; 56(3): 214–225.
  26. Mustonen A, Niemelä S, Nordström T, et al. Adolescent cannabis use, baseline prodromal symptoms and the risk of psychosis. Br J Psychiatry. 2018; 212(4): 227–233.
  27. Fratta W, Fattore L. Molecular mechanisms of cannabinoid addiction. Curr Opin Neurobiol. 2013; 23(4): 487–492.
  28. Cougle JR, Bonn-Miller MO, Vujanovic AA, et al. Posttraumatic stress disorder and cannabis use in a nationally representative sample. Psychol Addict Behav. 2011; 25(3): 554–558.
  29. Massot-Tarrús A, McLachlan RS. Marijuana use in adults admitted to a Canadian epilepsy monitoring unit. Epilepsy Behav. 2016; 63: 73–78.
  30. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington (DC): National Academies Press (US); 2017 Jan 12. PMID: 28182367. Therapeutic Effects of Cannabis and Cannabinoids. https://pubmed.ncbi.nlm.nih.gov/28182367/ (22/11/2021).
  31. European Monitoring Centre for Drugs and Drugs Addiction (2018), Medical use of cannabis and cannabinoids: questions and answers for policymaking, Publication Office of the European Union, Luxembourg. https://www.emcdda.europa.eu/publications/rapid-communications/medical-use-of-cannabis-and-cannabinoids-questions-and-answers-for-policymaking_en (17/01/2022).
  32. Medical Cannabis in Europe. European Industrial Pharmacists Group (EIPG). https://epig.eu/medical-cannabis-in-europe/ (17/01/2022).
  33. Lipnik-Štangelj M, Razinger B. A regulatory take on cannabis and cannabinoids for medicinal use in the European Union. Arh Hig Rada Toksikol. 2020; 71(1): 12–18.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl